Skin Side Effects Linked to Semaglutide, Liraglutide, and Tirzepatide

Incretin-based therapies for obesity are associated with increased reports of dermatological adverse events.

• The study focuses on three specific medications: semaglutide, liraglutide, and tirzepatide.
• Dermatological adverse events may occur more frequently with these therapies as their use for obesity rises.
• Characterization of these cutaneous adverse events includes their spectrum and clinical features.
• Recognition of these adverse events is becoming more important as incretin-based therapies gain popularity.

Simplified